Periscope Capital’s BioPlus Acquisition Corp. Class A Ordinary Shares BIOS Stock Holding History

Periscope Capital’s Portfolio BIOS Stock Details BIOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-250,000	Closed	-$2.71M	–	625
2023 Q3	$2.71M	Hold	250,000	–	–	0.31%	118
2023 Q2	$2.66M	Sell	250,000 -229,145	-48%	-$2.41M	0.21%	165
2023 Q1	$5M	Buy	479,145 +268,725	+128%	+$2.78M	0.23%	153
2022 Q4	$2.16M	Buy	210,420 +64,920	+45%	+$659K	0.09%	341
2022 Q3	$1.46M	Sell	145,500 -104,300	-42%	-$1.04M	0.04%	539
2022 Q2	$2.5M	Hold	249,800	–	–	0.07%	504
2022 Q1	$2.47M	Buy	+249,800	New	+$2.47M	0.06%	525

Periscope Capital's BIOS Position: Q4 2023 in Review

Periscope Capital sold out of BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) in Q4 2023, closing a stake of 250,000 shares — an estimated $2.71M sold.

Periscope Capital first reported a position in BIOS in Q1 2022 and held it in 7 quarters. The position peaked at $5M in Q1 2023. 0 funds tracked by Wall St. Rank hold BIOS as of Q4 2023.

Periscope Capital reported no remaining BioPlus Acquisition Corp. Class A Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Periscope Capital sold 250,000 BioPlus Acquisition Corp. Class A Ordinary Shares shares in Q4 2023, an estimated $2.71M.
Periscope Capital first reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares in Q1 2022 and held it in 7 quarters.
Periscope Capital's BioPlus Acquisition Corp. Class A Ordinary Shares position peaked at $5M in Q1 2023.
0 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Class A Ordinary Shares as of Q4 2023.

Based on Periscope Capital's 13F filing for Q4 2023, filed 13 Feb 2024.